Strategy for the Prediction and Selection of Drug Substance Salt Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strategy for the Prediction and Selection of Drug Substance Salt Forms
Through consideration of the ionic equilibria of acids and bases, one may readily calculate the formation constant of a salt species solely on the basis of knowledge of the pKA value of the acid and the pKB value of the base.


Pharmaceutical Technology


then Equation 22 becomes:



When converted to the Sørensen scale, Equation 23 becomes:



Equation 25 can be used to make rapid deductions regarding the strength of a particular salt species. Suppose one were contemplating forming a salt between an acid having a pK A value of 4.79 and a base having a pK A value of 9.45. For the base, it would follow that the pK B would equal 4.55, and because pK W = 14.0 at 25 °C, the pK S of the salt would equal -4.66, and that K S would equal approximately 45,710 . A reaction characterized by an equilibrium constant of this magnitude would clearly go to completion, and one would predict that the salt in question would be formed without difficulty.

The ability to calculate K S enables one to estimate the relative position of the equilibrium described by Equation 16. Consider the solution prepared by mixing an acid at an initial concentration of C HA with a base at an initial concentration of C B . For a salt form having a 1:1 stoichiometry, the concentrations of conjugate acid and conjugate base formed in the reaction would necessarily be equal. If the resulting ionic concentrations are represented by X, then the concentration of residual acid would equal (C HAX) and the concentration of residual base would equal (C B X). Equation 24 would then have the form:



Because obtaining the solution of Equation 26 by means of the quadratic equation is trivial, the degree of formation of a salt through the mixing of equimolar amounts of acid and base (i.e., C HA = C B ) can be easily calculated. For example, if log(K S ) = 2, it follows that X = 0.9091, indicating that equation 16 would proceed 90.91% to completion. Similarly, if log(K S ) = 3, then X = 0.9693 and the efficiency of salt formation would be 96.93%. If log(K S ) = 4, the salt would be 99.01% formed, and if log(K S ) = 5, then the salt would be 99.68% formed. It is often stated in the literature that if the ionization constants of the acid and base involved in salt formation differ by 2 or 3 pK units, then the salt would be formed. Use of the log(K S ) quantity serves to place the old empirical rule on a more fundamental basis and facilitates calculation of the actual percentage of salt formation.

Knowledge of the log(K S ) quantity also permits one to deduce the degree of disproportionation that would be anticipated if one were to dissolve a salt in pure water. If the X factor of Equation 26 represents the fraction of salt being formed by the reaction of the acid and base, then it follows that the fraction of salt that would disproportionate would necessarily be given by (1–X), and its percentage as 100 times that quantity.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here